{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:22:05Z","timestamp":1792077725410,"version":"4.4.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The development of high-throughput techniques like next-generation sequencing (NGS) has unraveled the genetic profile of cancer. In this review, we discuss the role of NGS on the diagnostic, risk stratification, and follow-up of patients with acute myeloid leukemia (AML).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>NGS has become an essential tool in clinical practice for AML management. Therefore, efforts are being made to improve its applications, automation, and turnaround time. Other high-throughput techniques, such as whole genome sequencing or RNA-sequencing, can be also used to this end. However, not all institutions may be able to implement these approaches. NGS is being investigated for measurable residual disease (MRD) assessment, especially with the development of error-correction NGS. New data analysis approaches like machine learning are being investigated in order to integrate genomic and clinical data and develop comprehensive classifications and risk scores.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>NGS has proven to be a useful approach for the analysis of genomic alterations in patients with AML, which aids patient management. Current research is being directed at reducing turnaround time and simplifying processes so that these techniques can be universally integrated into clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000899","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T12:00:35Z","timestamp":1663156835000},"page":"723-728","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["The role of next-generation sequencing in acute myeloid leukemia"],"prefix":"10.1097","volume":"34","author":[{"given":"Marta","family":"Llop","sequence":"first","affiliation":[{"name":"Molecular Biology Unit, Service of Clinical Analysis. Hospital Universitari i Polit\u00e8cnic La Fe"},{"name":"CIBERONC CB16\/12\/00284"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sargas","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Barrag\u00e1n","sequence":"additional","affiliation":[{"name":"Molecular Biology Unit, Service of Clinical Analysis. Hospital Universitari i Polit\u00e8cnic La Fe"},{"name":"CIBERONC CB16\/12\/00284"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"R2-20250526","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12920-020-0671-8","article-title":"Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring","volume":"13","author":"Crowgey","year":"2020","journal-title":"BMC Med Genomics"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","article-title":"Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission","volume":"6","author":"Jentzsch","year":"2022","journal-title":"Blood Adv"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ng.3756","article-title":"Precision oncology for acute myeloid leukemia using a knowledge bank approach","volume":"49","author":"Gerstung","year":"2017","journal-title":"Nat Genet"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"R10-20250526","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jmoldx.2018.09.009","article-title":"Clinical utility of a next-generation sequencing panel for acute myeloid leukemia diagnostics","volume":"21","author":"Alonso","year":"2019","journal-title":"J Mol Diagn"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2019004583","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?","volume":"136","author":"R\u00f6llig","year":"2020","journal-title":"Blood"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1182\/blood-2021-148926","article-title":"Evaluation of a rapid automated next generation sequencing assay for precision medicine in acute myeloid leukemia","volume":"138","author":"Andrew","year":"2021","journal-title":"Blood"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3324\/haematol.2020.263806","article-title":"Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project","volume":"106","author":"Sargas","year":"2021","journal-title":"Haematologica"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, Version 2.2021: featured updates to the NCCN guidelines","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"e0227986","DOI":"10.1371\/journal.pone.0227986","article-title":"Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design","volume":"15","author":"Aguilera-Diaz","year":"2020","journal-title":"PLoS One"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/genes12060846","article-title":"Delineation of molecular lesions in acute myeloid leukemia patients at diagnosis: integrated next generation sequencing and cytogenomic studies","volume":"12","author":"Papuc","year":"2021","journal-title":"Genes (Basel)"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.3390\/cancers13123001","article-title":"Next generation cytogenetics in myeloid hematological neoplasms: detection of CNVs and translocations","volume":"13","author":"Chicano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3324\/haematol.2018.194258","article-title":"Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing","volume":"104","author":"Mack","year":"2019","journal-title":"Haematologica"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2021-153302","article-title":"Clinical impact of copy number variation revealed by next generation sequencing in acute myeloid leukemia","volume":"138","author":"Janusz","year":"2021","journal-title":"Blood"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40291-020-00484-5","article-title":"Analytical and potential clinical performance of oncomine myeloid research assay for myeloid neoplasms","volume":"24","author":"Park","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jmoldx.2021.07.019","article-title":"The application of targeted RNA sequencing for KMT2A-partial tandem duplication identification and integrated analysis of molecular characterization in acute myeloid leukemia","volume":"23","author":"Dai","year":"2021","journal-title":"J Mol Diagn"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N Engl J Med"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-021-01153-0","article-title":"Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia","volume":"35","author":"Rapaport","year":"2021","journal-title":"Leukemia"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/bloodadvances.2020003709","article-title":"Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets","volume":"5","author":"Stratmann","year":"2021","journal-title":"Blood Adv"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cll.2021.03.014","article-title":"Molecular genetics of pediatric acute myeloid leukemia","volume":"41","author":"Krock","year":"2021","journal-title":"Clin Lab Med"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2643-3230.BCD-21-0049","article-title":"Integrative genomic analysis of pediatric myeloid-related acute leukemias identifies novel subtypes and prognostic indicators","volume":"2","author":"Fornerod","year":"2021","journal-title":"Blood cancer Discov"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/s41467-022-30233-7","article-title":"Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers","volume":"13","author":"Shukla","year":"2022","journal-title":"Nat Commun"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg.2017.96","article-title":"Cancer transcriptome profiling at the juncture of clinical translation","volume":"19","author":"Cie\u015blik","year":"2018","journal-title":"Nat Rev Genet"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/s41467-021-22625-y","article-title":"A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia","volume":"12","author":"Docking","year":"2021","journal-title":"Nat Commun"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ijlh.13711","article-title":"Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: one institute's practical clinical experience","volume":"44","author":"McGowan","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3324\/haematol.2020.254623","article-title":"Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for postremission strategies or relapse","volume":"106","author":"Onecha","year":"2021","journal-title":"Haematologica"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","article-title":"Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"11","author":"Kim","year":"2021","journal-title":"Blood Cancer J"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.2020010603","article-title":"Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia","volume":"138","author":"Awada","year":"2021","journal-title":"Blood"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat Commun"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:06:20Z","timestamp":1748300780000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000899","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]}}}